Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 4,300 shares of the company’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $60.07, for a total value of $258,301.00. Following the sale, the chief executive officer now owns 121,441 shares of the company’s stock, valued at $7,294,960.87. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Masimo Corp. (NASDAQ:MASI) opened at 59.97 on Monday. The firm has a market cap of $2.96 billion, a PE ratio of 31.45 and a beta of 0.70. Masimo Corp. has a one year low of $33.03 and a one year high of $60.52. The firm has a 50-day moving average price of $59.11 and a 200-day moving average price of $51.48.
Masimo Corp. (NASDAQ:MASI) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.16. The company earned $172.64 million during the quarter, compared to analysts’ expectations of $166.02 million. Masimo Corp. had a return on equity of 29.07% and a net margin of 15.40%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.36 earnings per share. On average, equities analysts expect that Masimo Corp. will post $2.02 EPS for the current fiscal year.
Several brokerages recently weighed in on MASI. BTIG Research restated a “hold” rating on shares of Masimo Corp. in a research report on Friday, August 5th. Zacks Investment Research downgraded Masimo Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Piper Jaffray Cos. restated an “overweight” rating and set a $55.00 price objective (up from $52.00) on shares of Masimo Corp. in a research report on Friday, August 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $63.00 target price (up previously from $60.00) on shares of Masimo Corp. in a report on Thursday, August 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $52.60.
Several institutional investors have recently made changes to their positions in MASI. Aperio Group LLC boosted its position in shares of Masimo Corp. by 27.3% in the first quarter. Aperio Group LLC now owns 15,761 shares of the company’s stock valued at $659,000 after buying an additional 3,379 shares during the period. Virginia Retirement System bought a new position in shares of Masimo Corp. during the first quarter valued at $1,452,000. Pacad Investment Ltd. bought a new position in shares of Masimo Corp. during the first quarter valued at $519,000. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Masimo Corp. by 0.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 56,685 shares of the company’s stock valued at $2,372,000 after buying an additional 400 shares during the period. Finally, Ngam Advisors L.P. bought a new position in shares of Masimo Corp. during the first quarter valued at $461,000. Institutional investors own 79.88% of the company’s stock.
About Masimo Corp.
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.